Cargando…

Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?

Osteoporosis is a chronical, systemic skeletal disorder characterized by an increase in bone resorption, which leads to reduced bone density. The reduction in bone mineral density and therefore low bone mass results in an increased risk of fractures. Osteoporosis is caused by an imbalance in the nor...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonk, Christian Horst, Shoushrah, Sarah Hani, Babczyk, Patrick, El Khaldi-Hansen, Basma, Schulze, Margit, Herten, Monika, Tobiasch, Edda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836178/
https://www.ncbi.nlm.nih.gov/pubmed/35163315
http://dx.doi.org/10.3390/ijms23031393
_version_ 1784649613352894464
author Tonk, Christian Horst
Shoushrah, Sarah Hani
Babczyk, Patrick
El Khaldi-Hansen, Basma
Schulze, Margit
Herten, Monika
Tobiasch, Edda
author_facet Tonk, Christian Horst
Shoushrah, Sarah Hani
Babczyk, Patrick
El Khaldi-Hansen, Basma
Schulze, Margit
Herten, Monika
Tobiasch, Edda
author_sort Tonk, Christian Horst
collection PubMed
description Osteoporosis is a chronical, systemic skeletal disorder characterized by an increase in bone resorption, which leads to reduced bone density. The reduction in bone mineral density and therefore low bone mass results in an increased risk of fractures. Osteoporosis is caused by an imbalance in the normally strictly regulated bone homeostasis. This imbalance is caused by overactive bone-resorbing osteoclasts, while bone-synthesizing osteoblasts do not compensate for this. In this review, the mechanism is presented, underlined by in vitro and animal models to investigate this imbalance as well as the current status of clinical trials. Furthermore, new therapeutic strategies for osteoporosis are presented, such as anabolic treatments and catabolic treatments and treatments using biomaterials and biomolecules. Another focus is on new combination therapies with multiple drugs which are currently considered more beneficial for the treatment of osteoporosis than monotherapies. Taken together, this review starts with an overview and ends with the newest approaches for osteoporosis therapies and a future perspective not presented so far.
format Online
Article
Text
id pubmed-8836178
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88361782022-02-12 Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad? Tonk, Christian Horst Shoushrah, Sarah Hani Babczyk, Patrick El Khaldi-Hansen, Basma Schulze, Margit Herten, Monika Tobiasch, Edda Int J Mol Sci Review Osteoporosis is a chronical, systemic skeletal disorder characterized by an increase in bone resorption, which leads to reduced bone density. The reduction in bone mineral density and therefore low bone mass results in an increased risk of fractures. Osteoporosis is caused by an imbalance in the normally strictly regulated bone homeostasis. This imbalance is caused by overactive bone-resorbing osteoclasts, while bone-synthesizing osteoblasts do not compensate for this. In this review, the mechanism is presented, underlined by in vitro and animal models to investigate this imbalance as well as the current status of clinical trials. Furthermore, new therapeutic strategies for osteoporosis are presented, such as anabolic treatments and catabolic treatments and treatments using biomaterials and biomolecules. Another focus is on new combination therapies with multiple drugs which are currently considered more beneficial for the treatment of osteoporosis than monotherapies. Taken together, this review starts with an overview and ends with the newest approaches for osteoporosis therapies and a future perspective not presented so far. MDPI 2022-01-26 /pmc/articles/PMC8836178/ /pubmed/35163315 http://dx.doi.org/10.3390/ijms23031393 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tonk, Christian Horst
Shoushrah, Sarah Hani
Babczyk, Patrick
El Khaldi-Hansen, Basma
Schulze, Margit
Herten, Monika
Tobiasch, Edda
Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
title Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
title_full Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
title_fullStr Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
title_full_unstemmed Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
title_short Therapeutic Treatments for Osteoporosis—Which Combination of Pills Is the Best among the Bad?
title_sort therapeutic treatments for osteoporosis—which combination of pills is the best among the bad?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836178/
https://www.ncbi.nlm.nih.gov/pubmed/35163315
http://dx.doi.org/10.3390/ijms23031393
work_keys_str_mv AT tonkchristianhorst therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad
AT shoushrahsarahhani therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad
AT babczykpatrick therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad
AT elkhaldihansenbasma therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad
AT schulzemargit therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad
AT hertenmonika therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad
AT tobiaschedda therapeutictreatmentsforosteoporosiswhichcombinationofpillsisthebestamongthebad